JP6026013B2 - 新規キノロン誘導体 - Google Patents
新規キノロン誘導体 Download PDFInfo
- Publication number
- JP6026013B2 JP6026013B2 JP2015548889A JP2015548889A JP6026013B2 JP 6026013 B2 JP6026013 B2 JP 6026013B2 JP 2015548889 A JP2015548889 A JP 2015548889A JP 2015548889 A JP2015548889 A JP 2015548889A JP 6026013 B2 JP6026013 B2 JP 6026013B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydroxy
- oxo
- carboxamido
- acetic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- CWMXRILSIHZXEG-UHFFFAOYSA-N C=CCON(c(nccc1)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound C=CCON(c(nccc1)c1C(O)=C1C(NCC(O)=O)=O)C1=O CWMXRILSIHZXEG-UHFFFAOYSA-N 0.000 description 1
- OEQTZANVBJRUEO-UHFFFAOYSA-N C=CCON(c1cc(Oc2ccccc2)ccc1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound C=CCON(c1cc(Oc2ccccc2)ccc1C(O)=C1C(NCC(O)=O)=O)C1=O OEQTZANVBJRUEO-UHFFFAOYSA-N 0.000 description 1
- IIOLEQVHEMPYPZ-UHFFFAOYSA-N C=CCON(c1cccc(F)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound C=CCON(c1cccc(F)c1C(O)=C1C(NCC(O)=O)=O)C1=O IIOLEQVHEMPYPZ-UHFFFAOYSA-N 0.000 description 1
- CVSNVXIILYKIMZ-UHFFFAOYSA-N C=CCON(c1ccccc1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound C=CCON(c1ccccc1C(O)=C1C(NCC(O)=O)=O)C1=O CVSNVXIILYKIMZ-UHFFFAOYSA-N 0.000 description 1
- GTCQZZZLDABVRZ-UHFFFAOYSA-N CCCON(c1c(C(O)=C2C(NCC(O)=O)=O)[o]cc1)C2=O Chemical compound CCCON(c1c(C(O)=C2C(NCC(O)=O)=O)[o]cc1)C2=O GTCQZZZLDABVRZ-UHFFFAOYSA-N 0.000 description 1
- UZDVTRISPQJECU-UHFFFAOYSA-N CCON(c([s]cc1)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CCON(c([s]cc1)c1C(O)=C1C(NCC(O)=O)=O)C1=O UZDVTRISPQJECU-UHFFFAOYSA-N 0.000 description 1
- RBJCMLGWQHEMOF-UHFFFAOYSA-N CCON(c(c(C(O)=C1C(NCC(O)=O)=O)ccc2)c2OC)C1=O Chemical compound CCON(c(c(C(O)=C1C(NCC(O)=O)=O)ccc2)c2OC)C1=O RBJCMLGWQHEMOF-UHFFFAOYSA-N 0.000 description 1
- LFTXYPKIUYJQNH-UHFFFAOYSA-N CN(CC(O)=O)C(C(C(N(c1ccccc11)OCc2ccccc2)=O)=C1O)=O Chemical compound CN(CC(O)=O)C(C(C(N(c1ccccc11)OCc2ccccc2)=O)=C1O)=O LFTXYPKIUYJQNH-UHFFFAOYSA-N 0.000 description 1
- USFGXCUQCQVPLQ-UHFFFAOYSA-N CON(c1c(C(O)=C2C(NCC(O)=O)=O)[s]cc1)C2=O Chemical compound CON(c1c(C(O)=C2C(NCC(O)=O)=O)[s]cc1)C2=O USFGXCUQCQVPLQ-UHFFFAOYSA-N 0.000 description 1
- JIXNFYSYVXWYNX-UHFFFAOYSA-N OC(CNC(C(C(N(c(c1c2)ccc2Oc2ncccc2)OCc2ccccc2)=O)=C1O)=O)=O Chemical compound OC(CNC(C(C(N(c(c1c2)ccc2Oc2ncccc2)OCc2ccccc2)=O)=C1O)=O)=O JIXNFYSYVXWYNX-UHFFFAOYSA-N 0.000 description 1
- NTVWLHJZZNPMRP-UHFFFAOYSA-N OC(CNC(C(C(N(c1c2cccn1)OCCc1ccc(C(F)(F)F)cc1)=O)=C2O)=O)=O Chemical compound OC(CNC(C(C(N(c1c2cccn1)OCCc1ccc(C(F)(F)F)cc1)=O)=C2O)=O)=O NTVWLHJZZNPMRP-UHFFFAOYSA-N 0.000 description 1
- JCIWRCFMPOQZPN-UHFFFAOYSA-N OC(CNC(C(C(N(c1c2cncn1)OCc1ccccc1)=O)=C2O)=O)=O Chemical compound OC(CNC(C(C(N(c1c2cncn1)OCc1ccccc1)=O)=C2O)=O)=O JCIWRCFMPOQZPN-UHFFFAOYSA-N 0.000 description 1
- GYICHNKMWXRAQM-UHFFFAOYSA-N OC(CNC(C(C(N(c1ccccc11)OCc2c[s]c(C(F)(F)F)n2)=O)=C1O)=O)=O Chemical compound OC(CNC(C(C(N(c1ccccc11)OCc2c[s]c(C(F)(F)F)n2)=O)=C1O)=O)=O GYICHNKMWXRAQM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3600MU2012 | 2012-12-24 | ||
| IN3600/MUM/2012 | 2012-12-24 | ||
| PCT/IN2013/000796 WO2014102818A1 (en) | 2012-12-24 | 2013-12-23 | Novel quinolone derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016503052A JP2016503052A (ja) | 2016-02-01 |
| JP2016503052A5 JP2016503052A5 (cg-RX-API-DMAC7.html) | 2016-06-23 |
| JP6026013B2 true JP6026013B2 (ja) | 2016-11-16 |
Family
ID=54148255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015548889A Active JP6026013B2 (ja) | 2012-12-24 | 2013-12-23 | 新規キノロン誘導体 |
Country Status (26)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3190104B1 (en) * | 2014-09-02 | 2021-10-27 | Sunshine Lake Pharma Co., Ltd. | Quinolinone compound and use thereof |
| WO2016045125A1 (en) | 2014-09-28 | 2016-03-31 | Merck Sharp & Dohme Corp. | Inhibitors of hif prolyl hydroxylase |
| CL2015003047A1 (es) * | 2015-10-15 | 2016-06-17 | Univ Chile | Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| CN108069957B (zh) * | 2016-11-09 | 2022-11-04 | 广东东阳光药业有限公司 | 脯氨酰羟化酶抑制剂及其用途 |
| US11021478B2 (en) | 2017-05-09 | 2021-06-01 | Kind Pharmaceutical | Indolizine derivatives and their application in medicine |
| AU2019223182B2 (en) | 2018-02-26 | 2021-08-19 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as HBV replication inhibitors |
| WO2021181360A1 (en) * | 2020-03-13 | 2021-09-16 | Cadila Healthcare Limited | Novel salts of quinolone compounds |
| US20230190731A1 (en) * | 2020-03-17 | 2023-06-22 | Zydus Lifesciences Limited | Formulation comprising hif prolyl hydroxylase inhibitors |
| EP4138825A1 (en) | 2020-04-20 | 2023-03-01 | Akebia Therapeutics Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| US20230241044A1 (en) * | 2020-05-29 | 2023-08-03 | Zydus Lifesciences Limited | Treatment for psoriasis and skin inflammatory diseases |
| CN115666517A (zh) * | 2020-06-01 | 2023-01-31 | 兹杜斯生命科学有限公司 | 炎性肠病的治疗 |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| IL305861A (en) * | 2021-03-19 | 2023-11-01 | Zydus Lifesciences Ltd | Treatment of sickle cell anemia |
| EP4308089A4 (en) * | 2021-03-19 | 2025-02-26 | Zydus Lifesciences Limited | QUINOLONE COMPOUND IN SOLID FORMS AND PROCESSES FOR THEIR PREPARATION |
| WO2022238745A1 (en) * | 2021-05-14 | 2022-11-17 | Zydus Lifesciences Limited | Topical pharmaceutical composition of hif prolyl hydroxylase inhibitors |
| WO2022251563A1 (en) | 2021-05-27 | 2022-12-01 | Keryx Biopharmaceuticals, Inc. | Pediatric formulations of ferric citrate |
| CN113549011B (zh) * | 2021-08-10 | 2023-05-09 | 广东东阳光药业有限公司 | 德度司他的共晶或盐及其制备方法和用途 |
| KR20240063900A (ko) * | 2021-09-20 | 2024-05-10 | 자이두스 라이프사이언시즈 리미티드 | 데시더스타트 입자 및 이의 조성물 |
| EP4539934A1 (en) * | 2022-06-24 | 2025-04-23 | Zydus Lifesciences Limited | Treatment for glomerular diseases |
| EP4565233A1 (en) * | 2022-08-01 | 2025-06-11 | Zydus Lifesciences Limited | Treatment for aplastic anemia (aa) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ270267A (en) | 1993-12-30 | 1997-03-24 | Hoechst Ag | 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions |
| NZ543448A (en) | 2003-06-06 | 2009-02-28 | Fibrogen Inc | Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin |
| US8703795B2 (en) * | 2005-03-02 | 2014-04-22 | Fibrogen, Inc. | Thienopyridine compounds, and methods of use thereof |
| WO2007038571A2 (en) * | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| ES2446416T3 (es) | 2005-12-09 | 2014-03-07 | Amgen, Inc. | Compuestos basados en quinolona que presentan actividad inhibidora de prolil hidroxilasa, composiciones y usos de los mismos |
| AR059733A1 (es) * | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| MX2008012734A (es) * | 2006-04-04 | 2009-01-29 | Fibrogen Inc | Compuestos pirrolo- y tiazolo-piridina como moduladores del factor inducible de hipoxia (hif). |
| WO2007136990A2 (en) * | 2006-05-16 | 2007-11-29 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2008010964A1 (en) * | 2006-07-17 | 2008-01-24 | Merck & Co., Inc. | 1-hydroxy naphthyridine compounds as anti-hiv agents |
| AU2007334321B2 (en) * | 2006-12-18 | 2012-03-08 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| CA2683758A1 (en) * | 2007-04-18 | 2008-10-30 | Merck & Co., Inc. | Novel 1,8-naphthyridine compounds |
| JP2010524942A (ja) * | 2007-04-18 | 2010-07-22 | アムジエン・インコーポレーテツド | プロリルヒドロキシラーゼを阻害するキノロン及びアザキノロン |
| CA2685216C (en) * | 2007-05-04 | 2014-07-08 | Amgen Inc. | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| WO2008137084A2 (en) * | 2007-05-04 | 2008-11-13 | Amgen Inc. | Diazaquinolones that inhibit prolyl hydroxylase activity |
| WO2008138060A1 (en) * | 2007-05-16 | 2008-11-20 | Cowper Norman T | System and method for maximising solids concentration of slurry pumped through a pipeline |
| WO2009070644A1 (en) * | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| CN101951777A (zh) * | 2008-02-25 | 2011-01-19 | 默沙东公司 | 四氢呋喃并吡啶酮 |
| EP2257169B1 (en) * | 2008-02-25 | 2013-06-05 | Merck Sharp & Dohme Corp. | Tetrahydrothieno pyridines |
| CN101951776A (zh) * | 2008-02-25 | 2011-01-19 | 默沙东公司 | 四氢-1h-吡咯稠合吡啶酮 |
| JP2011525924A (ja) * | 2008-06-25 | 2011-09-29 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| AR077417A1 (es) | 2009-07-17 | 2011-08-24 | Japan Tobacco Inc | Compuesto triazolopiridina y su accion como inhibidor de prolil hidroxilasa o agente inductor de la produccion de eritropoyetina |
| TW201109324A (en) * | 2009-08-20 | 2011-03-16 | Vifor Int Ag | Novel quinoline hepcidine antagonists |
| CN103608346B (zh) | 2011-02-02 | 2016-06-15 | 菲布罗根有限公司 | 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物 |
| US9034851B2 (en) | 2011-09-23 | 2015-05-19 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| CA2863279A1 (en) * | 2012-01-31 | 2013-08-08 | Toyama Chemical Co., Ltd. | Heterocyclic compound having anti-hiv activity |
-
2013
- 2013-12-23 KR KR1020157016080A patent/KR101733901B1/ko active Active
- 2013-12-23 EA EA201591195A patent/EA028402B1/ru not_active IP Right Cessation
- 2013-12-23 CA CA2894636A patent/CA2894636C/en active Active
- 2013-12-23 US US14/652,024 patent/US9394300B2/en active Active
- 2013-12-23 TR TR2018/02305T patent/TR201802305T4/tr unknown
- 2013-12-23 UA UAA201506784A patent/UA117122C2/uk unknown
- 2013-12-23 AU AU2013368843A patent/AU2013368843B2/en active Active
- 2013-12-23 MY MYPI2015001457A patent/MY175854A/en unknown
- 2013-12-23 WO PCT/IN2013/000796 patent/WO2014102818A1/en not_active Ceased
- 2013-12-23 SG SG11201504458XA patent/SG11201504458XA/en unknown
- 2013-12-23 BR BR112015014222-2A patent/BR112015014222B1/pt active IP Right Grant
- 2013-12-23 CN CN201380067856.4A patent/CN104903295B/zh active Active
- 2013-12-23 JO JOP/2013/0383A patent/JO3781B1/ar active
- 2013-12-23 JP JP2015548889A patent/JP6026013B2/ja active Active
- 2013-12-23 EP EP13828997.0A patent/EP2935221B1/en active Active
- 2013-12-23 NZ NZ708605A patent/NZ708605A/en unknown
- 2013-12-23 MX MX2015008233A patent/MX373392B/es active IP Right Grant
- 2013-12-23 AP AP2015008502A patent/AP2015008502A0/xx unknown
- 2013-12-23 TW TW102147766A patent/TWI598339B/zh active
- 2013-12-23 ES ES13828997.0T patent/ES2660288T3/es active Active
- 2013-12-27 AR ARP130105055A patent/AR094300A1/es active IP Right Grant
-
2015
- 2015-05-27 ZA ZA2015/03814A patent/ZA201503814B/en unknown
- 2015-05-29 MA MA38138A patent/MA38138A1/fr unknown
- 2015-06-01 IL IL239109A patent/IL239109B/en active IP Right Grant
- 2015-06-22 CL CL2015001802A patent/CL2015001802A1/es unknown
- 2015-06-23 PH PH12015501452A patent/PH12015501452B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6026013B2 (ja) | 新規キノロン誘導体 | |
| JP5269086B2 (ja) | ヒト免疫不全ウイルスの複製阻害薬 | |
| TWI721335B (zh) | 鹵代烯丙基胺類ssao/vap-1抑制劑及其用途 | |
| KR20100108337A (ko) | 사람 면역결핍 바이러스 복제의 억제제 | |
| JP6728061B2 (ja) | ＲＯＲγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療 | |
| EP3704113A1 (en) | Bridged bicyclic compounds as farnesoid x receptor modulators | |
| JP2020527588A (ja) | アデノシンアンタゴニストとしてのヘテロ環式化合物 | |
| WO2010130034A1 (en) | Inhibitors of human immunodeficiency virus replication | |
| EP2220084A1 (en) | Inhibitors of human immunodeficiency virus replication | |
| CA2931085A1 (en) | Cyclic sulfone and sulfoximine analogs and uses thereof | |
| JP2021533186A (ja) | ブロモドメインタンパク質阻害薬としてのイミノスルホン化合物、医薬組成物及びその医薬用途 | |
| WO2014070978A1 (en) | Inhibitors of cytomegalovirus | |
| WO2008067644A1 (en) | Inhibitors of hiv replication | |
| TWI748194B (zh) | 含有雙環核心部分之新穎lxr調節劑 | |
| JP2011513222A (ja) | テトラヒドロチエノピリジン | |
| US20200131144A1 (en) | Amine or (thio)amide containing lxr modulators | |
| HK1211022B (en) | Quinolone derivatives | |
| OA17332A (en) | Novel quinolone derivatives. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20150821 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150821 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160506 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20160506 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20160517 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160523 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160803 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160912 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161011 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6026013 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |